Abstract PO3-04-13: SUMIT-ELA: Phase 1b/2 combination of cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib and selective estrogen receptor degrader (SERD) elacestrant in advanced hormone receptor positive (HR+) breast cancer after CDK4/6i

Authors: Amita Patnaik, Silvia Antolin Novoa, Meritxell Bellet- Ezquerra, Francois-Clement Bidard, Valentina Boni, Maxime Brunet, Mario Campone, Carlos Garay, Raquel Gómez-Bravo, Sacha Howell, Rinath Jeselsohn, Simon Lord, Paolo Mazzei, Maria De Miguel, Erin Roesch, Agostina Stradella, Helene Vanacker, Cecile Vicier, Seth Wander, Glen Clack, Stuart McIntosh

Published: 2024-05-02

DOI: 10.1158/1538-7445.sabcs23-po3-04-13

Source: Full article